The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension.
The ability of some antihypertensive drugs to protect from vascular damage in hypertension might be partially due to their ability to control matrix metalloproteinase (MMP)-mediated extracellular matrix metabolism, which in turn may contribute to vascular remodeling. This study was designed to investigate whether treatment with felodipine or diltiazem has any effect on plasma levels of MMP-2 and MMP-9 in essential hypertensive patients. We measured plasma levels of active MMP-2 and MMP-9 in 72 hypertensive subjects and 45 controls, both before and after 6 months of treatment with felodipine (group A) or diltiazem (group B). Mean adjusted differences, before and after each treatment, for MMP-2 and MMP-9 levels were: 19.8 (P =.01) for MMP-2, 0.2 (P =.5) for MMP-9 (group A), and 1.4 (P =.4) for MMP-2, 0.2 (P =.7) for MMP-9 (group B). These findings show that MMP-2 level is raised by treatment with felodipine but not diltiazem, whereas MMP-9 is unaffected by either treatment.
Zervoudaki
Alexandra
A
Department of Cardiology, Athens University, Hippokratio Hospital, 3 Athan. Diakou Str., 15122 Marousi, Athens, Greece. fotvlast@otenet.gr
Economou
Emanuel
E
Pitsavos
Christos
C
Vasiliadou
Karmen
K
Aggeli
Constantina
C
Tsioufis
Konstantinos
K
Toutouza
Marina
M
Stefanadis
Christodoulos
C
Toutouzas
Pavlos
P
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003971:Diastole / Q000187:drug effects; D004110:Diltiazem / Q000627:therapeutic use; D015736:Felodipine / Q000627:therapeutic use; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000201:enzymology* / Q000503:physiopathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood* / Q000187:drug effects*; D020780:Matrix Metalloproteinase 9 / Q000097:blood* / Q000187:drug effects*; D008875:Middle Aged; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
D000959:Antihypertensive Agents; D015415:Biomarkers; D002121:Calcium Channel Blockers; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D004110:Diltiazem; D015736:Felodipine